The FDA approved Anzupgo for the treatment of moderate to severe chronic hand eczema in adults who do not adequately respond to or cannot receive topical corticosteroids, Leo Pharma announced in a ...

Prefilled syringe eliminates the need to reconstitute separate vials prior to administration and simplifies the vaccine process.

Officials with the Food and Drug Administration have approved the continued sales of tobacco-flavored e-cigarettes and refill cartridges by Juul Labs.

PHILADELPHIA-- (BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a prefilled syringe presentation of SHINGRIX (Zoster Vaccine ...

The FDA’s 2022 ban on Juul’s four varieties of tobacco and menthol-flavored pods and the e-cigarette device was stayed a month later after an appeal by the company.

Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat ...

Moderna's COVID-19 vaccine has received full approval from the U.S. Food and Drug Administration (FDA) for use in children with medical conditions that put them at higher risk of severe illness.

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA approves a new dosing regimen of the drug with an improved safety profile.

The FDA has approved garadacimab-gxii for prophylactic use in patients aged 12 years and older with hereditary angioedema, according to a press release from CSL Behring. The approval was based on ...

References: FDA approves updated label for Lilly’s Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer’s disease. News release. Eli Lilly and Company.

The FDA has approved sebetralstat (sold as Ekterly), the first-ever pill for people 12 and older with hereditary angioedema, a rare genetic disorder that causes sudden and painful swelling that ...

The treatment marks the only targeted oral treatment in patients with non–small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.